

CLAIMS

1. Use of a composition comprising an amount of a MASP-2 inhibitory monoclonal antibody, or antigen-binding fragment thereof, effective to inhibit MASP-2-dependent complement activation, in the manufacture of a medicament for treating a human subject suffering from idiopathic pneumonia syndrome following hematopoietic stem cell transplant (HSCT-IPS), wherein the MASP-2 inhibitory antibody or antigen-binding fragment thereof, comprises a heavy chain variable region comprising CDR-H1, CDR-H2 and CDR-H3 of the amino acid sequence set forth as SEQ ID NO:67 and a light chain variable region comprising CDR-L1, CDR-L2 and CDR-L3 of the amino acid sequence set forth as SEQ ID NO:70.
2. The use of claim 1, wherein the use further comprises identifying a human subject suffering from idiopathic pneumonia syndrome following hematopoietic stem cell transplant (HSCT-IPS) prior to the step of administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen-binding fragment thereof, effective to inhibit MASP-2-dependent complement activation.
3. The use of claim 1, wherein the subject has previously undergone an allogeneic hematopoietic stem cell transplant.
4. The use of claim 1, wherein the subject has previously undergone an autologous hematopoietic stem cell transplant.
5. The use of claim 1, wherein the MASP-2 inhibitory antibody or antigen-binding fragment thereof, comprises a heavy chain variable region comprising the amino acid sequence set forth as SEQ ID NO:67 and a light chain variable region comprising the amino acid sequence set forth as SEQ ID NO:70.